Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.

Muller S, Victoria Lai W, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, Ni A, Eguchi T, Travis WD, Ladanyi M, Zauderer MG, Sauter JL.

Mod Pathol. 2019 Sep 19. doi: 10.1038/s41379-019-0364-z. [Epub ahead of print]

PMID:
31537897
2.

Practical Application of Real-World Evidence in Developing Cancer Therapies.

Zauderer MG.

JCO Clin Cancer Inform. 2019 Jul;3:1-2. doi: 10.1200/CCI.19.00071. No abstract available.

3.

Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.

Zauderer MG, Jayakumaran G, DuBoff M, Zhang L, Francis JH, Abramson DH, Cercek A, Nash GM, Shoushtari A, Chapman P, D'Angelo S, Arnold AG, Siegel B, Fleischut MH, Ni A, Rimner A, Rusch VW, Adusumilli PS, Travis W, Sauter JL, Zehir A, Mandelker D, Ladanyi M, Robson M.

J Thorac Oncol. 2019 Jul 16. pii: S1556-0864(19)30559-3. doi: 10.1016/j.jtho.2019.07.002. [Epub ahead of print]

PMID:
31323388
4.

Nivo-lution in Mesothelioma.

Mansfield AS, Zauderer MG.

Clin Cancer Res. 2019 Sep 15;25(18):5438-5440. doi: 10.1158/1078-0432.CCR-19-1836. Epub 2019 Jul 17.

PMID:
31315884
5.

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI.

CA Cancer J Clin. 2019 Sep;69(5):402-429. doi: 10.3322/caac.21572. Epub 2019 Jul 8. Review.

6.

Creating a Synthetic Clinical Trial: Comparative Effectiveness Analyses Using an Electronic Medical Record.

Zauderer MG, Grigorenko A, May P, Kastango N, Wagner I, Caroline A, Kris MG.

JCO Clin Cancer Inform. 2019 Jun;3:1-10. doi: 10.1200/CCI.19.00037.

7.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

van Brummelen EMJ, Levchenko E, Dómine M, Fennell DA, Kindler HL, Viteri S, Gadgeel S, López PG, Kostorov V, Morgensztern D, Orlov S, Zauderer MG, Vansteenkiste JF, Baker-Neblett K, Vasquez J, Wang X, Bellovin DI, Schellens JHM, Yan L, Mitrica I, DeYoung MP, Trigo J.

Invest New Drugs. 2019 May 7. doi: 10.1007/s10637-019-00783-7. [Epub ahead of print]

PMID:
31065954
8.

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma.

Ladanyi M, Sanchez Vega F, Zauderer M.

Genome Med. 2019 Mar 26;11(1):18. doi: 10.1186/s13073-019-0631-0.

9.

Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.

Das R, Guan P, Wiener SJ, Patel NP, Gohl TG, Evans E, Zauderer M, Nichols KE.

Blood Adv. 2019 Mar 12;3(5):813-824. doi: 10.1182/bloodadvances.2018028886.

10.

"A Tool, Not a Crutch": Patient Perspectives About IBM Watson for Oncology Trained by Memorial Sloan Kettering.

Hamilton JG, Genoff Garzon M, Westerman JS, Shuk E, Hay JL, Walters C, Elkin E, Bertelsen C, Cho J, Daly B, Gucalp A, Seidman AD, Zauderer MG, Epstein AS, Kris MG.

J Oncol Pract. 2019 Apr;15(4):e277-e288. doi: 10.1200/JOP.18.00417. Epub 2019 Jan 28.

PMID:
30689492
11.

Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.

Clavijo PE, Friedman J, Robbins Y, Moore EC, Smith E, Zauderer M, Evans EE, Allen CT.

Cancer Immunol Res. 2019 Feb;7(2):282-291. doi: 10.1158/2326-6066.CIR-18-0156. Epub 2018 Dec 4.

PMID:
30514791
12.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J; TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M.

Cancer Discov. 2018 Dec;8(12):1548-1565. doi: 10.1158/2159-8290.CD-18-0804. Epub 2018 Oct 15.

PMID:
30322867
13.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

PMID:
30266660
14.

Photoactivable Glycolipid Antigens Generate Stable Conjugates with CD1d for Invariant Natural Killer T Cell Activation.

Veerapen N, Kharkwal SS, Jervis P, Bhowruth V, Besra AK, North SJ, Haslam SM, Dell A, Hobrath J, Quaid PJ, Moynihan PJ, Cox LR, Kharkwal H, Zauderer M, Besra GS, Porcelli SA.

Bioconjug Chem. 2018 Sep 19;29(9):3161-3173. doi: 10.1021/acs.bioconjchem.8b00484. Epub 2018 Aug 23.

15.

Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?

Escalon JG, Harrington KA, Plodkowski AJ, Zheng J, Capanu M, Zauderer MG, Rusch VW, Ginsberg MS.

J Comput Assist Tomogr. 2018 Jul/Aug;42(4):601-606. doi: 10.1097/RCT.0000000000000727.

16.

Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.

Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS.

Immunotherapy. 2017 Sep;9(11):913-927. doi: 10.2217/imt-2017-0052. Review.

17.

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.

Eguchi T, Kadota K, Mayor M, Zauderer MG, Rimner A, Rusch VW, Travis WD, Sadelain M, Adusumilli PS.

Oncotarget. 2017 Sep 12;8(44):77872-77882. doi: 10.18632/oncotarget.20845. eCollection 2017 Sep 29.

18.

A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.

Zauderer MG, Tsao AS, Dao T, Panageas K, Lai WV, Rimner A, Rusch VW, Adusumilli PS, Ginsberg MS, Gomez D, Rice D, Mehran R, Scheinberg DA, Krug LM.

Clin Cancer Res. 2017 Dec 15;23(24):7483-7489. doi: 10.1158/1078-0432.CCR-17-2169. Epub 2017 Sep 28.

19.

Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma.

Yorke ED, Jackson A, Kuo LC, Ojo A, Panchoo K, Adusumilli P, Zauderer MG, Rusch VW, Shepherd A, Rimner A.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):61-69. doi: 10.1016/j.ijrobp.2017.04.025. Epub 2017 Apr 27.

20.

Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial.

LaGanke C, Samkoff L, Edwards K, Jung Henson L, Repovic P, Lynch S, Stone L, Mattson D, Galluzzi A, Fisher TL, Reilly C, Winter LA, Leonard JE, Zauderer M.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e367. doi: 10.1212/NXI.0000000000000367. eCollection 2017 Jul.

21.

Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.

Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Zauderer M, Rudin CM, Karajannis MA, Hanemann CO, Giancotti FG.

Mol Cancer Ther. 2017 Aug;16(8):1693-1704. doi: 10.1158/1535-7163.MCT-16-0821. Epub 2017 May 3.

22.

Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.

Shaikh F, Zauderer MG, von Reibnitz D, Wu AJ, Yorke ED, Foster A, Shi W, Zhang Z, Adusumilli PS, Rosenzweig KE, Krug LM, Rusch VW, Rimner A.

J Thorac Oncol. 2017 Jun;12(6):993-1000. doi: 10.1016/j.jtho.2017.02.026. Epub 2017 Mar 21.

23.

Alcohol and lung cancer risk among never smokers: A pooled analysis from the international lung cancer consortium and the SYNERGY study.

Fehringer G, Brenner DR, Zhang ZF, Lee YA, Matsuo K, Ito H, Lan Q, Vineis P, Johansson M, Overvad K, Riboli E, Trichopoulou A, Sacerdote C, Stucker I, Boffetta P, Brennan P, Christiani DC, Hong YC, Landi MT, Morgenstern H, Schwartz AG, Wenzlaff AS, Rennert G, McLaughlin JR, Harris CC, Olivo-Marston S, Orlow I, Park BJ, Zauderer M, Barros Dios JM, Ruano Raviña A, Siemiatycki J, Koushik A, Lazarus P, Fernández-Somoano A, Tardon A, Le Marchand L, Brenner H, Saum KU, Duell EJ, Andrew AS, Szeszenia-Dabrowska N, Lissowska J, Zaridze D, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Holcatova I, Pesatori AC, Consonni D, Olsson A, Straif K, Hung RJ.

Int J Cancer. 2017 May 1;140(9):1976-1984. doi: 10.1002/ijc.30618. Epub 2017 Feb 27.

24.

Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.

Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, Woo KM, Shen R, Ginsberg MS, Yorke ED, Rice DC, Tsao AS, Rosenzweig KE, Rusch VW, Krug LM.

J Clin Oncol. 2016 Aug 10;34(23):2761-8. doi: 10.1200/JCO.2016.67.2675. Epub 2016 Jun 20.

25.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.

Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.

26.

Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?

Rimner A, Simone CB 2nd, Zauderer MG, Cengel KA, Rusch VW.

Lancet Oncol. 2016 Feb;17(2):e43-e44. doi: 10.1016/S1470-2045(16)00024-3. No abstract available.

PMID:
26868350
27.

Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.

Billé A, Krug LM, Woo KM, Rusch VW, Zauderer MG.

J Thorac Oncol. 2016 Feb;11(2):249-55. doi: 10.1016/j.jtho.2015.10.003. Epub 2015 Dec 10.

28.

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.

Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, Zauderer MG, Lolkema MP, Apt D, Yeh RF, Fredrickson JO, Spoerke JM, Koeppen H, Ware JA, Lauchle JO, Burris HA 3rd, de Bono JS.

Clin Cancer Res. 2016 Jun 15;22(12):2874-84. doi: 10.1158/1078-0432.CCR-15-2225. Epub 2016 Jan 19.

29.

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.

Li BT, Lou E, Hsu M, Yu HA, Naidoo J, Zauderer MG, Sima C, Johnson ML, Daras M, DeAngelis LM, Fleisher M, Kris MG, Azzoli CG.

PLoS One. 2016 Jan 5;11(1):e0146063. doi: 10.1371/journal.pone.0146063. eCollection 2016. Erratum in: PLoS One. 2016;11(3):e0152450.

30.

A new standard for malignant pleural mesothelioma.

Zauderer MG.

Lancet. 2016 Apr 2;387(10026):1352-1354. doi: 10.1016/S0140-6736(15)01311-2. Epub 2015 Dec 21. No abstract available.

31.

Immunomodulation of the tumor microenvironment by neutralization of Semaphorin 4D.

Evans EE, Paris M, Smith ES, Zauderer M.

Oncoimmunology. 2015 May 29;4(12):e1054599. eCollection 2015 Dec.

32.

Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials.

Fisher TL, Seils J, Reilly C, Litwin V, Green L, Salkowitz-Bokal J, Walsh R, Harville S, Leonard JE, Smith E, Zauderer M.

Cytometry B Clin Cytom. 2016 Mar;90(2):199-208. doi: 10.1002/cyto.b.21338. Epub 2015 Dec 24.

33.

Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.

Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK.

Clin Cancer Res. 2016 Feb 15;22(4):827-36. doi: 10.1158/1078-0432.CCR-15-0431. Epub 2015 Oct 7.

34.

Generation and preclinical characterization of an antibody specific for SEMA4D.

Fisher TL, Reilly CA, Winter LA, Pandina T, Jonason A, Scrivens M, Balch L, Bussler H, Torno S, Seils J, Mueller L, Huang H, Klimatcheva E, Howell A, Kirk R, Evans E, Paris M, Leonard JE, Smith ES, Zauderer M.

MAbs. 2016;8(1):150-62. doi: 10.1080/19420862.2015.1102813. Epub 2015 Oct 2.

35.

Localized malignant pleural mesothelioma with renal metastasis.

Zardawi SJ, Li BT, Zauderer MG, Wang JW, Atmore BB, Barnes TA, Pavlakis N, Mathur MN, Clarke S.

Oxf Med Case Reports. 2015 Jan 14;2015(1):170-2. doi: 10.1093/omcr/omu064. eCollection 2015 Jan.

36.

CXCL13 antibody for the treatment of autoimmune disorders.

Klimatcheva E, Pandina T, Reilly C, Torno S, Bussler H, Scrivens M, Jonason A, Mallow C, Doherty M, Paris M, Smith ES, Zauderer M.

BMC Immunol. 2015 Feb 12;16:6. doi: 10.1186/s12865-015-0068-1.

37.

Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease.

Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, Jonason A, Felczak B, Zhang W, Kovalik V, Waltl S, Hall G, Pouladi MA, Smith ES, Bowers WJ, Zauderer M, Hayden MR.

Neurobiol Dis. 2015 Apr;76:46-56. doi: 10.1016/j.nbd.2015.01.002. Epub 2015 Feb 3.

38.

Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody.

Leonard JE, Fisher TL, Winter LA, Cornelius CA, Reilly C, Smith ES, Zauderer M.

Mol Cancer Ther. 2015 Apr;14(4):964-72. doi: 10.1158/1535-7163.MCT-14-0924. Epub 2015 Feb 5.

39.

Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.

Evans EE, Jonason AS Jr, Bussler H, Torno S, Veeraraghavan J, Reilly C, Doherty MA, Seils J, Winter LA, Mallow C, Kirk R, Howell A, Giralico S, Scrivens M, Klimatcheva K, Fisher TL, Bowers WJ, Paris M, Smith ES, Zauderer M.

Cancer Immunol Res. 2015 Jun;3(6):689-701. doi: 10.1158/2326-6066.CIR-14-0171. Epub 2015 Jan 22.

40.

SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease.

Smith ES, Jonason A, Reilly C, Veeraraghavan J, Fisher T, Doherty M, Klimatcheva E, Mallow C, Cornelius C, Leonard JE, Marchi N, Janigro D, Argaw AT, Pham T, Seils J, Bussler H, Torno S, Kirk R, Howell A, Evans EE, Paris M, Bowers WJ, John G, Zauderer M.

Neurobiol Dis. 2015 Jan;73:254-68. doi: 10.1016/j.nbd.2014.10.008. Epub 2014 Oct 18.

41.

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.

Zauderer MG, Drilon A, Kadota K, Huberman K, Sima CS, Bergagnini I, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Riely GJ, Kris MG, Krug LM, Pietanza MC.

Lung Cancer. 2014 Nov;86(2):237-40. doi: 10.1016/j.lungcan.2014.08.007. Epub 2014 Aug 17.

42.

A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers.

Drilon A, Sugita H, Sima CS, Zauderer M, Rudin CM, Kris MG, Rusch VW, Azzoli CG.

J Thorac Oncol. 2014 Sep;9(9):1272-7. doi: 10.1097/JTO.0000000000000256.

43.

Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.

Rimner A, Spratt DE, Zauderer MG, Rosenzweig KE, Wu AJ, Foster A, Yorke ED, Adusumilli P, Rusch VW, Krug LM.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):394-401. doi: 10.1016/j.ijrobp.2014.05.032. Epub 2014 Jul 26.

44.

Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.

Zauderer MG, Kass SL, Woo K, Sima CS, Ginsberg MS, Krug LM.

Lung Cancer. 2014 Jun;84(3):271-4. doi: 10.1016/j.lungcan.2014.03.006. Epub 2014 Mar 14.

45.

Anti-CXCL13 antibody can inhibit the formation of gastric lymphoid follicles induced by Helicobacter infection.

Yamamoto K, Nishiumi S, Yang L, Klimatcheva E, Pandina T, Takahashi S, Matsui H, Nakamura M, Zauderer M, Yoshida M, Azuma T.

Mucosal Immunol. 2014 Sep;7(5):1244-54. doi: 10.1038/mi.2014.14. Epub 2014 Mar 19.

PMID:
24646940
46.

Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.

Zauderer MG, Bott M, McMillan R, Sima CS, Rusch V, Krug LM, Ladanyi M.

J Thorac Oncol. 2013 Nov;8(11):1430-3. doi: 10.1097/JTO.0b013e31829e7ef9.

47.
48.
49.

Important recent insights into the genetics and biology of malignant pleural mesothelioma.

McMillan R, Zauderer M, Bott M, Ladanyi M.

Ann Cardiothorac Surg. 2012 Nov;1(4):462-5. doi: 10.3978/j.issn.2225-319X.2012.10.09. No abstract available.

50.

Toxicity of initial chemotherapy in older patients with lung cancers.

Zauderer MG, Sima CS, Korc-Grodzicki B, Kris MG, Krug LM.

J Geriatr Oncol. 2013 Jan;4(1):64-70.

Supplemental Content

Loading ...
Support Center